2025-02-28 - Analysis Report
## Johnson & Johnson (JNJ) Stock Performance Review

**0. Key Figures & Initial Analysis:**

Johnson & Johnson (JNJ) is a multinational pharmaceutical, medical device, and consumer goods company.  The provided data shows a significant underperformance compared to the S&P 500 (VOO) over the analyzed period.  While JNJ showed a cumulative return of 40.59%, VOO achieved 112.87%, resulting in a substantial lag.  Further analysis is needed to determine the reasons behind this underperformance.

**1. Performance Comparison vs. S&P 500:**

* **JNJ Cumulative Return:** 40.59%
* **VOO Cumulative Return:** 112.87%
* **Return Difference:** -72.28%  (JNJ underperformed VOO by 72.28%)
* **Relative Underperformance:** 22.9% (This means JNJ's underperformance relative to VOO is at the 22.9th percentile of the historical range of their performance differences).

The Alpha and Beta analysis across different years shows inconsistent performance relative to the market. While some periods show positive alpha (outperformance), others reveal negative alpha, suggesting the stock's performance is not consistently superior to the market. Beta generally hovers around 0.0-0.4, indicating lower volatility than the overall market. The market capitalization consistently remains high, around $300B - $400B.


**2. Recent Price Movement:**

* **Closing Price:** $163.73
* **5-Day Moving Average:** $163.79
* **20-Day Moving Average:** $156.38
* **60-Day Moving Average:** $149.27

The price is slightly below the 5-day moving average, suggesting recent consolidation.  However, it's significantly above both the 20-day and 60-day moving averages, indicating a recent upward trend. The positive change from the previous close ($0.398) reflects a minor uptrend.


**3. Technical Indicators & Expected Return:**

* **RSI:** 75.83 – This indicates the stock is in overbought territory, suggesting a potential pullback.
* **PPO:** 0.48 – A positive PPO suggests bullish momentum.
* **Relative Strength Change (20-day):** +10.9% -  Shows a recent increase in relative strength, supporting the upward trend.
* **Expected Return:** -94.4% - This extremely negative expected return relative to the S&P 500 over the long term is concerning and needs further investigation.  It suggests the model predicts significant underperformance.  The reasons for this prediction warrant careful analysis.

**4. Recent Earnings Analysis:**

| Date       | EPS    | Revenue      |
|------------|--------|--------------|
| 2024-10-23 | $1.12  | $22.47 B     |
| 2024-07-25 | $1.95  | $22.45 B     |
| 2024-05-01 | $1.35  | $21.38 B     |
| 2024-02-16 | $1.68  | $21.39 B     |
| 2023-10-27 | $10.32 | $21.35 B     |

Earnings per share (EPS) shows significant volatility, with a particularly high EPS in October 2023. Revenue remains relatively stable around $21-$22 billion. This volatility in EPS needs further investigation to understand the underlying drivers.  The exceptionally high EPS in October 2023 compared to other quarters needs to be explained.


**5. Financial Information:**

**Revenue and Profitability:**

| Quarter    | Revenue     | Profit Margin |
|------------|-------------|---------------|
| 2024-12-31 | $22.52B     | 68.35%        |
| 2024-09-30 | $22.47B     | 69.01%        |
| 2024-06-30 | $22.45B     | 69.40%        |
| 2024-03-31 | $21.38B     | 69.55%        |
| 2023-12-31 | $21.39B     | 68.23%        |

Revenue is relatively stable and high. Profit margins are consistently high, averaging around 69%, indicating strong profitability.

**Capital and Profitability:**

| Quarter    | Equity      | ROE           |
|------------|-------------|---------------|
| 2024-12-31 | $71.49B     | 4.80%         |
| 2024-09-30 | $70.16B     | 3.84%         |
| 2024-06-30 | $71.54B     | 6.55%         |
| 2024-03-31 | $70.02B     | 4.65%         |
| 2023-12-31 | $68.77B     | 5.89%         |

Equity fluctuates slightly, but remains substantial. Return on Equity (ROE) shows some variability but generally remains positive, indicating efficient use of capital.

**6. Overall Analysis:**

JNJ's performance has lagged significantly behind the S&P 500, despite consistent revenue and high profit margins.  The volatile EPS, overbought RSI, and a highly negative projected long-term return relative to the S&P 500 raise concerns.  The discrepancy between recent strong financials and the pessimistic long-term return prediction needs further investigation.  It's crucial to understand the reasons behind the exceptionally high EPS in October 2023 and the model's prediction of significant underperformance.  More detailed analysis of macroeconomic factors, sector-specific trends, and the company's specific strategic initiatives is necessary for a comprehensive assessment.  Simply relying on historical data might not provide a sufficient explanation for the significant underperformance and projected future returns.
